Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: Data from the PROGRESS study
Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: Data from the PROGRESS study
复制标题
DOI：
10.1681/asn.2007020256
复制
发表时间：
2007-10-01
影响因子：
13.6
通讯作者：
Chalmers, John
中科院分区：
文献类型：
--
作者：
Perkovic, Vlado;Ninomiya, Toshiharu;Chalmers, John
慢性肾脏病 (CKD) 与心血管疾病的高风险相关，但缺乏有关降低该风险的干预措施有效性的证据。培哚普利预防复发性中风研究 (PROGRESS) 研究招募了 6105 名患有脑血管疾病的参与者，并将他们随机分配到基于培哚普利的降压治疗或安慰剂组。患有 CKD 的个体发生主要血管事件、中风和冠心病的风险大约高出 1.5 倍，并且死亡的可能性是其两倍以上（所有 P
Chronic kidney disease (CKD) is associated with a high risk of cardiovascular disease, but evidence regarding the effectiveness of interventions to reduce that risk is lacking. The Perindopril Protection against Recurrent Stroke Study (PROGRESS) study enrolled 6105 participants with cerebrovascular disease and randomly allocated them to perindopril-based blood pressure-lowering therapy or placebo. Individuals with CKD were at approximately 1.5-fold greater risk of major vascular events, stroke, and coronary heart disease, and were more than twice as likely to die (all P